NCT02844907View on ClinicalTrials.gov

Regulation of Insulin Secretion by the GLP-1 Receptor

PHASE4TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Insulin Secretion
Interventions
DRUG

Exendin (9-39)

Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.

DRUG

Dexamethasone

Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.

OTHER

Hyperglycemic Clamp

A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.

Trial Locations (1)

27705

Durham VA Medical Center, Durham, NC, Durham

Sponsors

Collaborators (1)

Durham VA Medical Center
All Listed Sponsors
collaborator

Durham VA Medical Center

FED

lead

VA Office of Research and Development

FED